Key statistics
On Tuesday, MediciNova Inc (4875:TYO) closed at 276.00, -12.10% below its 52-week high of 314.00, set on Jan 23, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 265.00 |
|---|---|
| High | 278.00 |
| Low | 265.00 |
| Bid | 275.00 |
| Offer | 278.00 |
| Previous close | 267.00 |
| Average volume | 79.15k |
|---|---|
| Shares outstanding | 49.15m |
| Free float | 47.83m |
| P/E (TTM) | -- |
| Market cap | 12.36bn JPY |
| EPS (TTM) | -38.50 JPY |
Data delayed at least 15 minutes, as of Feb 10 2026 06:30 GMT.
More ▼
- MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
- 2026 New Year’s Greetings from the CEO
- MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
- MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
- Message from the CEO to MediciNova Shareholders
- MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
- MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
- MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
- MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
- MediciNova to Present at the LD Micro Main Event XIX Investor Conference
More ▼
